Results 121 to 130 of about 34,271 (248)

B‐Lymphoblastic Leukemia Presenting as Bilateral Ovarian Masses in a 20‐Year‐Old Woman

open access: yesClinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Hematologic malignancies involving the ovaries are rare and may mimic ovarian carcinoma. We report a 20‐year‐old woman who presented with generalized body pain, bilateral ovarian masses, and abdominal adenopathy, initially suspected to have ovarian carcinoma.
Jennifer Cai   +4 more
wiley   +1 more source

Myelodysplastic Syndromes‐Transformed Acute Myeloid Leukemia With Concurrent DEK::CAN Fusion Gene Positivity and WT1 Overexpression: A Case Report and Literature Review

open access: yesCancer Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders with a risk of progression to acute myeloid leukemia (AML). MDS‐transformed AML (MDS‐AML) has a poor prognosis. The concurrent presence of DEK::CAN fusion gene positivity and WT1 overexpression is extremely rare and likely denotes a highly ...
Wanxiu Mao   +5 more
wiley   +1 more source

Clinical Images: Collapsing auricles and airways in relapsing polychondritis with myelodysplastic syndrome

open access: yes
ACR Open Rheumatology, Volume 8, Issue 10, October 2026.
Yuqing Dan, Liling Zhao, Qiong Fu
wiley   +1 more source

One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T‐cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized‐controlled trial

open access: yesHemaSphere, Volume 10, Issue 10, October 2026.
Abstract UKALL14 (NCT01085617) T‐cell arm was a phase 3, randomized‐controlled trial. Adults aged 25–65 years were randomized 1:1 at entry to receive standard of care (SOC) or SOC + nelarabine 1.5 g/m2 (Days 1, 3, and 5) to be administered following second induction. The primary end‐point was event‐free survival (EFS).
Clare J. Rowntree   +14 more
wiley   +1 more source

MEK inhibition achieves robust and durable responses in Erdheim–Chester disease

open access: yesHemaSphere, Volume 10, Issue 10, October 2026.
Abstract Erdheim–Chester disease (ECD) is a rare histiocytic neoplasm characterized by heterogeneous clinical manifestations and limited evidence to guide targeted therapy. While MEK inhibitors (MEKi) are increasingly used, data on their real‐world efficacy, durability, and safety remain incomplete.
Francesco Pegoraro   +34 more
wiley   +1 more source

Clinical and Cytogenomic Characterization of Three Patients With Distal 1q43q44 Deletion: Twin Sisters With a de novo Deletion and a Patient With der(1)t(1;21)(q43;q22.3)mat

open access: yesJournal of Clinical Laboratory Analysis, Volume 40, Issue 19, October 2026.
Distal 1q43q44 deletions lead to a consistent neurodevelopmental phenotype characterized by microcephaly, corpus callosum abnormalities, and developmental delay. Despite differences in genomic architecture, overlapping deletions affecting dosage‐sensitive genes such as AKT3, HNRNPU, and ZBTB18 define the core phenotype.
Ma. Guadalupe Domínguez‐Quezada   +6 more
wiley   +1 more source

Profile of HIV-Infected Hispanics with Pancytopenia

open access: yes, 2015
Pancytopenia is seen in late HIV infection; it is associated with medical complications and with decreased survival. We determined the prevalence of pancytopenia at baseline in a cohort of HIV-positive Hispanics living in Puerto Rico, and compared their ...
Diana Fernández-Santos   +3 more
core   +1 more source

Acute Myeloid Leukaemia Driven by Rare HNRNPH1::ERG Fusion Gene in an Adult, With Distinct Transcripts Detected by RNASeq at Diagnosis and Relapse: A Case Report

open access: yeseJHaem, Volume 7, Issue 5, October 2026.
ABSTRACT Acute myeloid leukaemia (AML) cases with rare fusion genes, such as ERG‐related fusions, constitute less than 1% of AML. They often present with a normal karyotype by conventional cytogenetics but are increasingly detected by RNA sequencing (RNAseq), although their characteristics and the utility of fusion genes as an MRD marker are poorly ...
Hannah Al‐Yousuf   +9 more
wiley   +1 more source

Reversible Eltrombopag‐Associated Bone Marrow Fibrosis With Hematologic Recovery After Drug Withdrawal in ASXL1‐Mutated Hypoplastic Myelodysplastic Syndrome: A Case Report

open access: yeseJHaem, Volume 7, Issue 5, October 2026.
ABSTRACT Hypoplastic myelodysplastic syndrome (MDS) often overlaps clinically with aplastic anemia and frequently involves clonal hematopoiesis. Thrombopoietin receptor agonists (TPO‐RAs), including eltrombopag, are increasingly used to treat cytopenias in hypoplastic marrow failure syndromes; however, their long‐term effects on clonal dynamics and ...
Kyoko Yoshihara   +7 more
wiley   +1 more source

Atypical Presentation of UBE2T‐Related Fanconi Anemia With Immune‐Mediated Thrombocytopenia and Hematopoietic Somatic Mosaicism: A Case Report

open access: yeseJHaem, Volume 7, Issue 5, October 2026.
ABSTRACT Fanconi anemia (FA) is a genetically heterogeneous disorder of chromosome instability leading to bone marrow failure (BMF) and other manifestations. We report a case of FA in which two atypical features initially obscured the diagnosis: the presence of T cell‐mediated thrombocytopenia, and somatic mosaicism leading to normal chromosome ...
Bridget T. Kiely, Alison A. Bertuch
wiley   +1 more source

Home - About - Disclaimer - Privacy